Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enfamil Breast Milk Composition Claims Should Be Modified - NARB

This article was originally published in The Tan Sheet

Executive Summary

Mead Johnson Advanced Formula Enfamil with Iron breast milk composition claims should be discontinued unless specific conditions are met, the National Advertising Review Board recommends, upholding an earlier National Advertising Division decision.

You may also be interested in...



Nestle Carnation Ad Claims "Denigrating" To Other Infant Formulas - NAD

Nestle USA should cease referring to competing infant formulas as "starter" formulas in its advertising for Carnation Follow-Up, the National Advertising Division of the Council of Better Business Bureaus rules in its May NAD Case Reports.

Nestle Carnation Ad Claims "Denigrating" To Other Infant Formulas - NAD

Nestle USA should cease referring to competing infant formulas as "starter" formulas in its advertising for Carnation Follow-Up, the National Advertising Division of the Council of Better Business Bureaus rules in its May NAD Case Reports.

Nestle Carnation Ad Claims "Denigrating" To Other Infant Formulas - NAD

Nestle USA should cease referring to competing infant formulas as "starter" formulas in its advertising for Carnation Follow-Up, the National Advertising Division of the Council of Better Business Bureaus rules in its May NAD Case Reports.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel